Evotec SE (EVO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report shows mixed signals: strong growth in Just-Evotec Biologics and EBITDA, but a decline in overall segment revenues and R&D spending. The Q&A reveals optimism for non-Sandoz revenues and AI adoption, but concerns about BMS revenue decline and lack of clarity on clinical plans. The market cap suggests moderate reactions to these mixed signals, resulting in a neutral stock price prediction.
Key Financial Performance
Group Revenues (Q4 2025) Increased by EUR 32.1 million or 14.5% to EUR 253.3 million year-over-year. Growth was driven by strong performance in Just-Evotec Biologics segment and offsetting unfavorable foreign exchange movements.
Group Revenues (Full Year 2025) Decreased by EUR 8.6 million or 1.1% to EUR 788.4 million year-over-year. Decline was primarily due to lower revenues in the Discovery and Preclinical Development (D&PD) segment and unfavorable foreign exchange movements.
D&PD Segment Revenues (Q4 2025) Declined by EUR 27.3 million or 16.6% to EUR 137.1 million year-over-year. Decline attributed to challenging early-stage drug discovery market and unfavorable foreign exchange movements.
D&PD Segment Revenues (Full Year 2025) Declined by EUR 82.5 million or 13.5% to EUR 528.9 million year-over-year. Decline attributed to challenging early-stage drug discovery market and unfavorable foreign exchange movements.
Just-Evotec Biologics Revenues (Q4 2025) Increased by EUR 59.4 million or 104.2% year-over-year. Growth driven by Sandoz partnership and incremental contribution from a license payment of approximately EUR 65 million.
Just-Evotec Biologics Revenues (Full Year 2025) Increased by EUR 73.8 million or 39.8% to EUR 259.4 million year-over-year. Growth driven by Sandoz partnership and other non-Sandoz and non-DoW customers.
Adjusted Group EBITDA (Q4 2025) Increased by EUR 29.5 million or 103.6% to EUR 58 million year-over-year. Growth driven by strong performance in Just-Evotec Biologics segment.
Adjusted Group EBITDA (Full Year 2025) Increased by EUR 18.5 million or 81.9% to EUR 41.1 million year-over-year. Growth driven by strong performance in Just-Evotec Biologics segment and cost control measures.
R&D Spending (Full Year 2025) Decreased to EUR 37.5 million or 4.8% of total revenue compared to EUR 50.9 million or 6.4% of total revenue in 2024. Reduction reflects cost control measures in a challenging macroeconomic environment.
Cash Liquidity (Year-End 2025) Stood at EUR 476 million, representing a strong balance sheet with a net cash position. Improvement reflects disciplined financial execution, monetization of technology leadership, and reduced CapEx spend by 38% year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Company Strategy: Introduced in 2025, focusing on scientific leadership, operational excellence, monetization of Just-Evotec Biologics, and capturing pipeline value.
Just-Evotec Biologics: Shifted to an asset-lighter, technology-focused partner enablement model. Achieved a $650 million agreement with Sandoz for 10 biosimilars.
AI and Computational Platforms: Expanded collaboration with the Gates Foundation to support 10 new molecule design projects over three years.
Sandoz Agreement: A $650 million deal for 10 biosimilars, with additional royalty potential.
Global Health Programs: Received a $10 million BioMaP-Consortium award from the U.S. government for monoclonal antibody biomanufacturing.
Cost Savings: Achieved over EUR 60 million in annualized cost savings and reduced capital expenditure by 60% in 2025.
Horizon Initiative: Launched to transform the operating model, focusing on operations, science, and commercial execution. Expected structural and financial benefits in the second half of 2026.
Bristol Myers Squibb Collaboration: Advanced molecular glue degraders into Phase I clinical study, generating $15 million in milestone payments.
EVOequity Strategy: Transitioned from investment to monetization phase, generating significant proceeds from equity stakes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Environment: Persistently challenging market conditions in 2025, including softness in early-stage biotech funding, have impacted financial performance and operational planning.
Operational Transformation: The Horizon initiative involves significant restructuring, including site closures and workforce reductions of approximately 800 positions, which could lead to operational disruptions and employee morale issues.
Revenue Dependency: Revenue fluctuations due to reliance on key partnerships, such as with Bristol Myers Squibb, and the cyclical nature of these collaborations, which have seen a decline in revenue contributions.
Foreign Exchange Movements: Unfavorable foreign exchange movements, particularly involving the U.S. dollar and British pound, have created additional headwinds to revenue.
Cost Management: Temporary elevated costs in the Just-Evotec Biologics segment due to the Sandoz transaction and higher material costs, which are expected to normalize but currently weigh on profitability.
Regulatory and Legal Processes: The Horizon transformation requires navigating complex legal and regulatory processes, which could delay implementation and realization of cost savings.
Economic Uncertainty: Budget cuts from the U.S. Department of War-related activities and broader economic uncertainties have impacted revenue streams and market stability.
Strategic Execution: Challenges in transitioning to a more capital-efficient operating model and ensuring the successful implementation of the Horizon initiative without disrupting ongoing customer and partner programs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Horizon Initiative: The Horizon initiative is expected to deliver structural and financial benefits starting in the second half of 2026. It includes operational, scientific, and commercial transformations, with a focus on streamlining operations, reducing costs, and improving commercial execution.
Discovery and Preclinical Development (D&PD): The company expects the total number of assets in Phase II to grow from 2 to 4 during 2026. Additionally, the D&PD segment is projected to achieve low to mid-single-digit revenue growth in 2026, with a recovery in the early-stage drug discovery market anticipated in the second half of the year.
Just-Evotec Biologics (JEB): JEB is transitioning to a high-margin, technology-driven business model. Non-Sandoz and non-DoW activities are expected to grow by about 40% in 2026. The segment will benefit from the removal of cost drag from the sale of the Toulouse site, contributing an estimated EUR 20 million year-on-year improvement in segment earnings.
2026 Financial Guidance: Group revenues are expected to range between EUR 700 million and EUR 780 million at current foreign exchange rates, with adjusted group EBITDA projected between EUR 0 million and EUR 40 million. Approximately 20%-30% of the EUR 75 million structural run rate savings from the Horizon initiative are expected to materialize in 2026.
Midterm Framework (2026-2030): Group revenues are projected to exceed EUR 1 billion by 2030, with an adjusted EBITDA margin reaching 20% by 2028 and exceeding that level by 2030. Margin expansion will be driven by structural savings, higher-margin revenue streams, and increased operating leverage.
Bristol Myers Squibb (BMS) Collaboration: The oncology collaboration with BMS is expected to transition into a realization phase, contributing approximately 50% of D&PD earnings growth between 2026 and 2028. Clinical stage programs are anticipated to complement the base business from 2027 onwards.
EVOequity Strategy: The company is transitioning from a cash-out to a cash-realization model, with recent divestments expected to generate significant cash proceeds and future upside from contingent milestone payments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the starting point for non-Sandoz, non-DoW revenues in the JEB segment for 2025?
A:Non-Sandoz, non-DoW revenue is expected to be approximately 30% of the overall Just business in 2025, growing from 25% in 2024 and projected to reach 50% by the end of 2026.
Q:Will the BMS remuneration plan shift to a royalty milestone-based model?
A:Yes, the program was designed to transition to an increasing amount of milestones and royalty payments over time.
Q:What are the current clinical plans for BMS's asset EVT8683 in Phase I?
A:The management cannot comment on BMS's exact plans but believes the asset is progressing through a thorough Phase I trial, with expectations to move into Phase II for Alzheimer's.
Q:What is the company's confidence in market recovery for 2026?
A:The company sees a mix of market recovery and its own commercial efforts driving growth. While the funding situation in biotech has improved, it is difficult to separate market recovery from internal efforts.
Q:What is the expected impact of BMS on 2026 revenues?
A:A high single-digit percentage decline in revenues from BMS is expected in 2026 compared to 2025.
Q:What are the expectations for milestone payments in 2026?
A:The company expects milestone payments similar to the $10 million recognized in Q1 2025, with additional payments in the second half. The €100 million mentioned includes cash payments associated with deals, recognized over time.
Q:What is the risk of customer disruption due to Horizon implementation?
A:The company believes there is no material risk of customer disruption. They have been in constant dialogue with customers and received no negative feedback.
Q:What are the expected revenues and royalty streams post the Toulouse site sale?
A:Revenues from new products and licenses are expected to ramp up by 2028, reaching around 10% of Just revenue. Royalties will begin beyond 2028, linked to the LOE dates of drugs coming off patent.
Q:Is AI adoption by pharma and biotech an opportunity for the JEB business?
A:Yes, AI is an integral part of the company's drug discovery platforms and is used extensively in collaborations like BMS. Both pharma/biotech and AI companies are utilizing their services.
Q:What underpins the low single-digit growth expectation for D&PD in the second half of 2026?
A:Growth is expected from a mix of stand-alone business, integrated business, and strategic deals. Improved sales order trajectory and strategic deals are contributing factors.
Q:Are there other meaningful stakes in the company's portfolio that could lead to upside?
A:Yes, the company has 29-30 companies in its portfolio as of December 2025, with some assets showing significant potential. However, timing and quantification of upside are uncertain.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the exact clinical plans for BMS's asset EVT8683, citing that it is not their place to comment on BMS's intentions. Additionally, they did not provide specific details on the timing or quantification of potential upside from their portfolio of companies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief
Communications Investor
DPD
Discovery
EUR exchange
EUR period
EUR revenue
Global Communications
Horizon transformation
Member
Phase II
Sandoz transaction
advancement
agreement
asset Phase
balance sheet
engagement
evolution
excellence
exchange rate
framework
group revenue
headwind
improvement
indicator
kidney
license
margin expansion
monetization
partnership
phase
pillar
portfolio
realization
revenue EUR
saving
segment Slide
shift
stake
EVO Transcript
Evotec SE (EVO) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals a mixed performance with negative revenue growth and gross margin challenges, countered by optimistic guidance and strategic partnerships. Liquidity remains stable, and management expresses confidence in achieving guidance, but lacks specificity in quarterly forecasts. The market cap suggests moderate sensitivity to news, leading to a neutral prediction for stock price movement over the next two weeks.
Evotec SE (EVO) Q4 2025 Earnings Call Transcript
Unknown4-8
The earnings report shows mixed signals: strong growth in Just-Evotec Biologics and EBITDA, but a decline in overall segment revenues and R&D spending. The Q&A reveals optimism for non-Sandoz revenues and AI adoption, but concerns about BMS revenue decline and lack of clarity on clinical plans. The market cap suggests moderate reactions to these mixed signals, resulting in a neutral stock price prediction.
Evotec SE (EVO) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call summary reveals several negative aspects: a 7% decline in group revenues, negative EBITDA, and economic uncertainties. The Q&A highlights concerns about market recovery, profitability, and management's unclear responses. Despite some positive aspects like JEB growth and strategic transactions, the overall sentiment remains negative due to the revenue decline and financial challenges. The market cap indicates a small-cap company, which typically reacts more strongly to negative news, supporting a prediction of a negative stock price movement (-2% to -8%) over the next two weeks.
Evotec SE (EVO) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presents a mixed picture. Strong partnerships and technology leadership are positive, but management's reluctance to provide specifics in the Q&A raises concerns. While strategic partnerships and AI integration are promising, the lack of concrete guidance and details, particularly regarding the Sandoz deal and revenue specifics, may temper enthusiasm. Additionally, the market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.
EVO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
